Advancing intravenous medication safety through clinical pharmacist-led IV compatibility surveillance

In critical care units, IV incompatibility–related medication errors continue to occur mainly because staff awareness is limited, standardized compatibility references are not readily available, and pharmacists are not consistently involved in IV line management. These issues increase the risk of adverse drug events and can negatively affect patient safety. Therefore, a structured quality improvement initiative is necessary to improve compliance and minimize IV incompatibility incidents.

• Reduce the Time to Intervention (TTI) for pharmacist-led clinical interventions to ≤20 minutes from prescription review.
• Improve the clinical intervention acceptance rate by treating physicians to ≥90%.
• Increase the proportion of IV compatibility-related clinical interventions to ≥80% through proactive identification and prevention of Y-site incompatibilities.
• Develop and implement a standardized IV compatibility reference chart based on commonly encountered incompatible IV drug pairs to support safe Y-site co-administration and facilitate evidence-based clinical decision-making.

Intervention:

The current Y-site IV compatibility management process has several gaps compared with best practices. Compatibility assessment is primarily based on nurses’ memory or outdated reference charts, with no standardized verification system or real-time electronic compatibility database. There is no formal hospital-wide standard operating procedure (SOP) for Y-site compatibility, resulting in inconsistent practices. Pharmacist involvement is largely reactive, occurring only after incompatibility is identified, rather than through proactive review during medication order verification. Staff receive limited periodic training on IV compatibility, with no structured annual competency assessment. Compatibility checks are not routinely documented before Y-site co-administration, limiting process accountability. Additionally, the electronic medical record (EMR) lacks automated alerts for IV incompatibilities, increasing the risk of administration errors. There is no systematic monitoring of incompatibility incidents through key performance indicators (KPIs) or control charts, and no hospital-specific list of high-risk medications requiring Y-site compatibility precautions.

Methodology – Six sigma

Following implementation of the pharmacist-led IV compatibility surveillance program, measurable improvement was observed across all key indicators over a ~5-month evaluation period (September 2025–February 2026). The Intervention Ratio rose from a baseline of 9.8% to 23%, while the Acceptance Rate of pharmacist interventions improved from 30.7% to 50.7%, with individual post-improvement months reaching as high as 86%. Average Time to Intervention (TTI) reduced significantly from 45 minutes to 25 minutes, exceeding the project’s target of 20 minutes closely. Interventions per 1000 patients on IV therapy increased from 37.7 to 90.5, reflecting stronger detection and reporting culture. The Sigma level improved from 0.9 to 2, indicating a meaningful shift in process capability.

Beyond these quantitative gains, the initiative strengthened pharmacist-nurse collaboration, introduced standardized documentation before Y-site co-administration, and built staff awareness of high-risk IV drug combinations through structured training. Collectively, these results translate into reduced risk of adverse drug events, better IV line patency, safer infusion therapy, and improved overall medication safety culture in the critical care units, directly supporting the project’s goals around compliance, timely intervention, and patient safety.

Key challenges during implementation included limited baseline awareness among nursing and clinical staff regarding IV compatibility risks, absence of a standardized compatibility reference or protocol, and inconsistent pharmacist involvement in IV line management prior to the project. High ICU workload, multiple infusions through limited lumen access, and interruptions during emergency situations further complicated consistent compatibility checking. Absence of EMR-integrated alerts and a formal audit system meant incidents were historically under-reported and difficult to track.

Critical success factors that enabled progress included strong sponsorship from Clinical Pharmacology as project champion, structured staff training sessions, development of an IV compatibility handbook and reference posters, and introduction of daily pharmacist-led IV review rounds. Standardized documentation formats, regular audit and feedback cycles, and close pharmacy-nursing collaboration were essential to sustaining compliance. Weekly data monitoring and mitigation planning for risks like staff resistance and non-compliance also proved critical to embedding the change into routine practice.

The project highlighted that IV incompatibility errors are largely preventable through structured, pharmacist-led intervention rather than reliance on staff memory or informal practices. Proactive pharmacist involvement during order verification, rather than reactive correction after incidents, was identified as the single most impactful lever for improvement. The findings also revealed persistent gaps that require continued attention: absence of EMR-based automated incompatibility alerts, lack of a hospital-defined high-risk drug list, and infrastructure limitations around lumen allocation in ICU settings. These remain unresolved and represent priority areas for the Control phase and future accreditation readiness. Overall, the assessment demonstrates a credible, data-backed shift toward stronger medication safety practices, but sustained improvement will depend on institutionalizing technology support, formalizing SOPs hospital-wide, and maintaining ongoing monitoring to prevent process drift once the initial project momentum settles.